Aim: The slow coronary flow (SCF), a distinct angiographic finding characterized by presence of Thrombolysis in Myocardial Infarction (TIMI) –2 flow in the absence of coronary disease, pathophysiologically related to endothelial and microvascular dysfunction. Previous studies, it has been shown that oral diprydamole could correct the SCF angiographically. The aim of this study is to evaluate the effect of diprydamole on endothelial functions tested from the forearm, SCF which is physiopathologically related to endothelial dysfunction.
Material and methods: 28 patients (22 male, 6 female, mean age 50±8.0) with angiographically-proven slow coronary flow at one or more coronary arterieswere included in study. All drugs that may interact with endothelial functions were stopped 15 days before the study. At the end of 15 days, baseline brachial artery Doppler examinations were performed and diprydamole 75 mg tid. was given to all patients during the nex tone month, and at the end of one month, brachial artery Doppler examinations were reperformed.
Results: When the results of the patients before and after use of diprydamole were compared, it was observed that post-diprydamole flow mediated vasodilatation (FMD) value was significantly higher than the basal FMD value (FMD-prediprydamole: 2.7%±1.9, FMD-postdiprydamole: 3.1%±1.8, p=0.001). Nitroglyserine (NTG), thus shows endothelium-independent vasodilatation, showed no significant difference in prediprydamole and postdiprydamole period (NTG-prediprydamole: 13.1%±3.3, NTG-postdiprydamole: 13.0%±3.0, p=0.9). It was also noted that mean corrected TIMI frame count showed strong but inverse relationship with baseline FMD percent (r=-0.26, p
|
